Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism

Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus

(2010) Mitchell G. Lawrence et al.   ENDOCRINE REVIEWS

Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment

(2010) Kiyoshi Takagi et al.   ENDOCRINE-RELATED CANCER

Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

(2010) Gauri Sabnis et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators?

(2009) Pan Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Androgen Receptor Inhibits Estrogen Receptor-  Activity and Is Prognostic in Breast Cancer

(2009) A. A. Peters et al.   CANCER RESEARCH

Estrogen signaling pathway and its imaging in human breast cancer

(2009) Shin-ichi Hayashi et al.   CANCER SCIENCE

Human Cytosolic Hydroxysteroid Dehydrogenases of the Aldo-ketoreductase Superfamily Catalyze Reduction of Conjugated Steroids

(2009) Yi Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In situestrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology

(2009) Hironobu Sasano et al.   PATHOLOGY INTERNATIONAL

Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor

(2009) Yutaka Yamamoto et al.   Breast Cancer

The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

(2008) Matthew J. Sikora et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction

(2008) M. Matsumoto et al.   ENDOCRINE-RELATED CANCER

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY